Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

SARS-CoV-2 has mutated during the global pandemic leading to viral adaptation to medications and vaccinations. Here we describe an engineered human virus receptor, ACE2, by mutagenesis and screening for binding to the receptor binding domain (RBD). Three cycles of random mutagenesis and cell sorting...

Descripción completa

Detalles Bibliográficos
Autores principales: Higuchi, Yusuke, Suzuki, Tatsuya, Arimori, Takao, Ikemura, Nariko, Mihara, Emiko, Kirita, Yuhei, Ohgitani, Eriko, Mazda, Osam, Motooka, Daisuke, Nakamura, Shota, Sakai, Yusuke, Itoh, Yumi, Sugihara, Fuminori, Matsuura, Yoshiharu, Matoba, Satoaki, Okamoto, Toru, Takagi, Junichi, Hoshino, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217473/
https://www.ncbi.nlm.nih.gov/pubmed/34155214
http://dx.doi.org/10.1038/s41467-021-24013-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217473/
https://www.ncbi.nlm.nih.gov/pubmed/34155214
http://dx.doi.org/10.1038/s41467-021-24013-y

Ejemplares similares